Innovating Works

AMPHORA

Financiado
ACOUSTIC MARKERS FOR ENHANCED REMOTE SENSING OF RADIATION DOSES
Approximately 50% of all cancer patients receive radiation therapy as part of their treatment. The aim is hereby to maximise tumor irradiation and to minimize healthy tissue irradiation. This implies a need for appropriate dosimet... Approximately 50% of all cancer patients receive radiation therapy as part of their treatment. The aim is hereby to maximise tumor irradiation and to minimize healthy tissue irradiation. This implies a need for appropriate dosimetry strategies that can effectively measure the actual radiation dose imparted on the tumor. However, state-of-the-art dosimetry cannot quantify the dose distribution in (and around) the tumor, hereby inhibiting the full potential of radiotherapy. AMFORA aims to develop a non-invasive in-situ dosimetry system for radiation therapy with the potential of on-line dose assessment by casting ultrasound contrast agents (UCAs) into dose sensing theranostic devices. UCAs will be upgraded to injectable dose-sensitive and targeted devices that gather in tumor tissue and translate imparted radiation dosage into a modulation of their acoustic response upon ultrasound interrogation. Tailored ultrasound imaging and advanced signal processing algorithms will be developed to extract the (change in) acoustic signature of UCAs from backscatter data and to translate this information into a 2D or 3D dose distribution map. The specific objectives of this project are the design, development and pre-clinical validation of the aforementioned UCA based dosimetry system and a customised ultrasound read-out technology. Upon successful completion, AMFORA will have enabled the assessment of the effective radiation dose distribution in (and around) the tumor, offering an advanced and objective means to compare and evaluate treatment efficacy of different radiotherapy modalities. Such novel technology would revolutionize quality assurance and treatment follow up in radiotherapy, which also unmistakably will lead to increased patient safety and improved treatment protocols. Moreover, AMFORA is expected to trigger an avalanche of novel technologies for radiation therapy delivery and to pave the way for other in-vivo UCA based distributed sensing applications. ver más
30/04/2022
KU Leuven
4M€
Duración del proyecto: 56 meses Fecha Inicio: 2017-08-08
Fecha Fin: 2022-04-30

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2022-04-30
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
FETOPEN-01-2016-2017: FET-Open research and innovation actions
Cerrada hace 8 años
Presupuesto El presupuesto total del proyecto asciende a 4M€
Líder del proyecto
KATHOLIEKE UNIVERSITEIT LEUVEN No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5